OMTX-705

DERIO, Spain--(BUSINESS WIRE)--ONCOMATRYX, a Spanish biopharmaceutical company developing Quantum ADCs against the tumor microenvironment, has successfully raised $67 million to foster the clinical development of novel candidates. The funding round was led by the company’s institutional investors, including a $28 million strategic investment from the Spanish Government through Centro para el Desarrollo Tecnologico e Innovacion (CDTI), $18 million from Kutxa Fundazioa, $12 million from the Basque Government (Gobierno Vasco) and Ekarpen VC, $2 million from BBK, as well as Spanish and international private investors. This endorsement highlights the confidence in ONCOMATRYX pioneering Quantum ADCs to treat metastatic solid tumors. “We are thrilled to count on the continued support of our existing investors,” said Dr. Laureano Simon, CEO of ONCOMATRYX. “This funding validates the clinical progress of our lead candidate OMTX705 and equips us to take OMTX105 and other Quantum ADCs into clinical trials.” “This operation is an example of the public-private collaboration model that the Spanish Government promotes to strengthen our science and innovation system. Backing Oncomatryx means backing more advanced oncology therapies and positioning Spain at the forefront of biotechnology in the service of health,” said Diana Morant, Minister of Science, Innovation and Universities of the Spanish Government, whose department is contributing $28 million through CDTI’s Innvierte strategic co-investment programme. “This investment is fully aligned with our objectives of fostering innovation and competitiveness, reinforcing our commitment to transformative projects with a tangible impact on our ecosystem,” said Eluska Sukia, Head of Investments at Kutxa Fundazioa, which is scaling its stake in Oncomatryx from 1.7% to 7.4% through an $18 million commitment. “With this investment, we are reinforcing our commitment to building a highly specialised biotechnology sector, which we consider strategic for the competitiveness and diversification of the Basque industrial base,” said Mikel Jauregi, Minister of Industry, Energy Transition and Sustainability of the Basque Government, contributing $12 million alongside Ekarpen VC. About Oncomatryx Oncomatryx has developed a proprietary Antibody-Drug Conjugates platform that targets Cancer-Associated Fibroblasts in the microenvironment of metastatic solid tumors. AI tools and Quantum Computing assist Oncomatryx scientists in ADC design and candidate selection. Proprietary payloads, dual payloads and conjugation chemistry strategies foster a unique ADC+ platform, complemented by an ADC Fill & Finish facility under development in San Sebastián. Oncomatryx’s pioneering Quantum ADCs against immunosuppressive CAFs are developed in collaboration with prestigious universities, hospitals and research centers in US and Europe. Phase Ib-II clinical results of OMTX705, a first-in-class ADC targeting Fibroblast Activation Protein in Cancer-Associated Fibroblasts, will be presented at major Oncology conferences throughout 2026. https://clinicaltrials.gov/ct2/show/NCT05547321?term=oncomatryx&draw=2&rank=1

LUND, Sweden, May 6, 2025 /PRNewswire/ -- TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is deepening its collaboration with Oncomatryx, a biopharmaceutical company developing novel antibody-drug conjugates (ADCs) targeting the tumor microenvironment. TFS will support a newly initiated Phase Ib clinical trial evaluating OMTX705—an anti-fibroblast activation protein antibody-drug conjugate (FAP-ADC)— in patients with advanced or metastatic pancreatic adenocarcinoma. The trial will be conducted across sites in Spain and the United States. According to the World Cancer Research Foundation, pancreatic cancer remains one of the deadliest malignancies globally, accounting for more than 510,000 new cases and over 466,000 deaths annually. Despite advances in oncology, treatment options for patients with advanced or metastatic disease remain limited. The five-year survival rate for pancreatic cancer continues to hover below 10%, underscoring the urgent need for new and more effective treatment options. This Phase Ib study builds on an earlier collaboration between TFS and Oncomatryx during a Phase I trial evaluating OMTX705 as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. The promising results from that study laid the foundation for this next phase of development and exemplified the consistent performance, deep therapeutic expertise, and oncology specialization that Oncomatryx values in its continued partnership with TFS. "Our continued collaboration with Oncomatryx reflects a shared commitment to accelerating the development of innovative therapies for challenging cancers like pancreatic adenocarcinoma," said Kris O'Brien, Vice President and Head of Oncology & Rare Diseases at TFS. "TFS brings deep therapeutic insight and operational agility to every program we support—helping to move promising science forward where it's needed most." "We're entering an exciting new phase in the clinical development of OMTX705," said Laureano Simón, CEO of Oncomatryx. TFS has proven to be a trusted, expert partner—key to advancing our science toward patients who urgently need new options." TFS brings over two decades of experience in oncology research, supporting clinical trials across solid tumors, hematological malignancies, and rare cancers. With a focus on agility, scientific rigor, and global reach, TFS has successfully guided numerous early-phase and late-phase oncology programs from concept to clinic. Through its long-standing partnerships, including this renewed collaboration with Oncomatryx, TFS continues to empower its partners with tailored clinical solutions—advancing science with the ultimate goal of enriching the lives of patients worldwide. Backed by strong financial support following a €25 million fundraising round completed at the end of 2024, and with Phase I clinical data expected at major oncology conferences throughout 2025, the OMTX705 program is gaining momentum and drawing increased attention as a promising new approach for hard-to-treat tumors like pancreatic adenocarcinoma. About TFS HealthScience TFS HealthScience is a full-service, global Contract Research Organization (CRO) that partners with biotechnology and pharmaceutical companies to advance innovative treatments and improve patient outcomes. With operations across 40 countries, TFS and its strategic partners provide tailored strategic resourcing solutions and clinical development services in specialized therapeutic areas, including dermatology, internal medicine, neuroscience, oncology, and ophthalmology. Dedicated to empowering partners and enriching lives, TFS offers flexible solutions that combine global reach with the agility and responsiveness of a mid-sized CRO. For more information, visit . About Oncomatryx Oncomatryx has developed a proprietary Antibody-Drug Conjugates platform that targets Cancer-Associated Fibroblasts in the microenvironment of metastatic solid tumors. Oncomatryx pioneering ADCs against immunosuppressive CADs are developed in collaboration with prestigious universities, hospitals, and research centers in the USA and Europe. Phase I clinical results of OMTX705, a novel ADC targeting Fibroblast activation Protein (FAP) in Cancer-Associated Fibroblasts, will be presented at major oncology conferences along 2025. For more information, visit . Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED